PARP1 and non-small cell lung carcinoma: The combination of PARPi and angiogenic inhibitor has been shown to be effective as a first-line or second-line maintenance regimen to synergistically exert antitumor effects in OC, breast cancer, (BC), colon cancer (CRC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and prostate cancer (PC) 20, 21, which prompts us to further evaluate the therapeutic effect of the combination of PARP inhibitor Niraparib and anti-angiogenic Brivanib on OC.